Kalytera cannabidiol platform to target GvHD

Kalytera cannabidiol platform to target GvHD

Kalytera Therapeutics (TSX-V:KALY) has put its bone repair and osteoporosis research programs on the back burner in order to focus development of a new cannabidiol (CBD) therapeutic for the treatment of acute Graft versus Host Disease (GvHD).

Read More

In conversation with Chiara Russo

In conversation with Chiara Russo

As a specialty pharmaceuticals analyst with Cantor Fitzgerald for the past 2 1/2 years, Chiara Russo covers developmental-stage companies that are on the cusp of changing the medical landscape as we know it. A philosophy major with an MBA from the Olin School of Business at Babson College, Ms. Russo was a R&D innovation consultant for Cubist Pharmaceuticals before becoming a sell-side equity research analyst. On the Street, she has been a research associate at ThinkEquity and VP and specialty pharmaceuticals analyst at Janney Montgomery Scott. In this interview with BioTuesdays.com, Ms. Russo discusses industry trends and some of the stocks she likes.

Read More

BioTime leading advances in regenerative medicine

BioTime leading advances in regenerative medicine

BioTime (NYSE MKT, TASE:BTX) has multiple data milestones scheduled this year in its two lead regenerative medicine programs: OpRegen in dry AMD and Renevia in facial aesthetics.

Read More

Clearside out front targeting back-of-the-eye diseases

Clearside out front targeting back-of-the-eye diseases

Using a novel ocular injection platform to deliver drug to the suprachroidal space (SCS) at the back of the eye, Clearside Biomedical (NASDAQ:CLSD) is relentless pursuing treatments for blinding diseases with a late-stage pipeline for macular edema associated with uveitis and retinal vein occulusion and DME, as well as an early development program for wet AMD.

Read More

In conversation with Mohit Trikha

In conversation with Mohit Trikha

As chief scientific officer, EVP and head of closely held Triphase Accelerator, Mohit Trikha has parlayed a successful 20-year track record in oncology drug development into a home run, selling Triphase’s first asset, a proteasome inhibitor known as marizomib, to Celgene (NASDAQ:CELG). Prior to joining Triphase, Dr. Trikha was associate VP of clinical development at Ambit Biosciences; director of BioOncology and early development at Genentech; and assistant director of oncology research at J&J’s Centocor. 

Read More

Athersys poised to launch pivotal stroke study next summer

Athersys poised to launch pivotal stroke study next summer

After receiving a Special Protocol Assessment (SPA) from the FDA at the end of September, Athersys (NASDAQ:ATHX) hopes to launch a pivotal trial next summer administering its intravenous MultiStem cell therapy in patients following an ischemic stroke.

Read More

GeneNews aims to fix compliance gap in early cancer screening

GeneNews aims to fix compliance gap in early cancer screening

GeneNews (TSX:GEN) is addressing the major issue in earlycancer screening - patient reluctance with inconvenient and intrusive screening methods - with a suite of differentiated molecular diagnostic tests that rely on a convenient in-office blood draw to find cancers of the colon, lung, breast and prostate, early.

Read More

In conversation with Jason Kolbert

In conversation with Jason Kolbert

As head of healthcare research and as the senior biotechnology analyst with Maxim Group, Jason Kolbert has worked extensively in the healthcare sector. This includes pharma experience with Schering-Plough in Japan, as a fund manager and as an equity analyst for the past 20 years. 

Read More

In conversation with Dr. Chad Larson

In conversation with Dr. Chad Larson

As an advisor and consultant with Cyrex Laboratories, a clinical immunology lab, Dr. Chad Larson holds a Doctor of Naturopathic Medicine degree from Southwest College of Naturopathic Medicine and a Doctor of Chiropractic degree from Southern California University of Health Sciences. 

Read More

NeuroproteXeon targets Q2 start of Phase 3 Xenex trial

NeuroproteXeon targets Q2 start of Phase 3 Xenex trial

Closely-held NeuroproteXeon has received agreement on a special protocol assessment from the FDA for a Phase 3 trial of its inhaled pharmaceutical grade product, XENEX, a xenon gas formulation, as a neuroprotecter against brain cell death following acute neurologic injury, such as cardiac arrest.

Read More

William Blair analyst discusses Hep B space

William Blair analyst discusses Hep B space

As a partner and biotechnology analyst with William Blair & Co., Y. Katherine Xu was recognized in 2010 by the Financial Times/StarMine “World’s Top Analysts” listing, ranking No. 7 overall for stock-picking in the U.S., and No. 2 for stock-picking in biotech in 2011. She also received the No. 2 ranking in The Wall Street Journal’s “Best on the Street” listing in 2011. Prior to joining William Blair in 2011, Ms. Xu was a SVP and senior biotech analyst at Wedbush Securities; VP and senior biotech analyst at Credit Suisse; and a senior biotech analyst at Pacific Growth Equities. Before her move into equity research, Ms. Xu worked in investment banking for two years. In this interview with BioTuesdays.com, Ms. Xu discusses her industry-leading research report entitled, Hepatitis B: The Next Frontier, and some of her best investment ideas in the Hep B space.

Read More

Mesoblast developing multiple cell-based products

Mesoblast developing multiple cell-based products

Mesoblast (NASDAQ:MESO; ASX:MSB) has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of late-stage product candidates.

“This technology has the potential to target advanced stages of diseases, with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions,” CEO and managing director, Dr. Silviu Itescu, says in an interview with BioTuesdays.com.

Dr. Itescu explains Mesoblast’s MLCs are rare cells and central to blood vessel maintenance, repair and regeneration, largely via secretion of growth factors, which act on neighboring endothelial cells to promote blood vessel regeneration and function.

Read More

COTI approaching critical inflection point

COTI approaching critical inflection point

As it transitions from a discovery and technology platform-focused organization to a clinical stage biotech company, Critical Outcome Technologies (OTCQB:COTQF; TSX-V:COT) is approaching a critical inflection point by mid-2017 with its lead program, COTI-2, in in gynaecological cancers.

COTI-2 is currently being evaluated in a Phase 1 clinical study at two premier cancer centers in the U.S.

“We’ve assembled an impressive amount of supportive preclinical data in the past for COTI-2, and are excited to be evaluating in the clinic this potentially significant therapeutic option for women suffering from debilitating gynecological cancers, such as ovarian cancer,” Alison Silva, president, says in an interview with BioTuesdays.com.

Read More